LAS VEGAS — Inflammatory bowel disease clinical trials underrepresent racial and ethnic minority groups, according to a presentation at the ACG Annual Scientific Meeting.

“Enrollment rates in IBD clinical trials are low for all patient groups. The underrepresentation of racial and ethnic minority groups in IBD clinical trials revealed by our analysis are highly relevant to the rapidly changing demographics in the United States,” Jellyana Peraza, MD, of the department of medicine at the Albert Einstein College of Medicine at Montefiore Medical Center, said during the

Full Article: